1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: TPH/SCU-IMed 01/08, NCT00838019
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 to 60
Sponsor: Other
Protocol IDs: CIK#2/2007, NMRC/1097/2006, NCT00460694
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 to 75
Sponsor: Other
Protocol IDs: AMC-UUCM-2008-0383, 2008-0383, NCT00823524
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-103, NCT00975767
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VITC-003, NCT01050621
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2004-0223, NCT00412594
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 11300A, NCT00683046
|
|
11.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P071203, MnDPDP04, IDRCB 2008-A000198-39, NCT00727922
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412D2201, NCT00782067
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 70
Sponsor: NCI, NHLBI
Protocol IDs: 606, U01 HL069294, NCT00864227
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 152/2008/U/Sper, NCT00886522
|
|
15.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 60
Sponsor: Other
Protocol IDs: CRUK-UCL-RIC-UCBT, RIC UCBT, CRUK-UCL-RIC-UCBT, EUDRACT-2004-003845-41, EU-20946, NCT00959231
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 09-0713, NCT00914849
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P2 L-D AB, NCT00917826
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090005, 09-C-0005, NCT00923013
|
|
19.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 64 and under
Sponsor: Other
Protocol IDs: FHCRC-2212.00, NCI-2009-01244, NCT00968630
|
|
20.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0908-04; IUCRO-0256, NCT00975975
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 09-0679-04, NCT00997386
|
|
22.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 0 to 75
Sponsor: Other
Protocol IDs: FHCRC-2241.00, NCI-2009-01334, NCT01008462
|
|
23.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 19 to 75
Sponsor: Other
Protocol IDs: 083-09, NCI-2009-01552, NCT01044745
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: CHNY 525, AAAB2879, NCT01049854
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1311002, SNX-5422-CLN1-002, NCT00595686
|
